Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celularity Equity Warrants Exp 16 July 2026 CELUW

Financial Services Healthcare Biotechnology
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent... see more

Recent & Breaking News (NDAQ:CELUW)

Celularity Inc. Announces Receipt of Nasdaq Notification

GlobeNewswire 6 hours ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

GlobeNewswire 7 days ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

GlobeNewswire 9 days ago

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

GlobeNewswire November 7, 2024

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

GlobeNewswire October 23, 2024

Celularity Provides Corporate Update

GlobeNewswire October 22, 2024

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

GlobeNewswire October 18, 2024

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound(TM) Product from Sequence LifeScience, Inc.

GlobeNewswire October 16, 2024

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Celularity Appoints Richard J. Berman to its Board of Directors

GlobeNewswire August 28, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

GlobeNewswire August 23, 2024

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

GlobeNewswire July 31, 2024

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 3, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

GlobeNewswire May 24, 2024

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

GlobeNewswire May 14, 2024

Celularity Inc. to Host Investor and Analyst Research & Development Day

GlobeNewswire April 22, 2024

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

GlobeNewswire April 19, 2024

Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024

GlobeNewswire April 18, 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

GlobeNewswire April 15, 2024

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

GlobeNewswire April 8, 2024